Platinum distribution inintraperitoneal tumors afterintraperitoneal cisplatin treatment

Abstract

The spatial distribution of platinum (Pt) in the kidney was studied by an autoradiographic technique, in which cisplatin (CDDP) was replaced by 195mPt-labeled CDDP, and by proton-induced X-ray emission (PIXE). Although both studies demonstrated comparable spatial distribution patterns, PIXE had the advantage that Pt concentrations could be determined quantitatively, in contrast to the relative information obtained by the autoradiographic technique. Using PIXE, the distribution of Pt in i.p. tumors was studied after i.p. administration of CDDP. The highest Pt concentrations were always found on the periphery of tumors, indicating that the periphery was exposed to a higher drug concentration than the center. Dose was correlated to the concentration of CDDP at both the center and the periphery (r = 0.99). The Pt concentration in the periphery was usually higher by a factor of 2-3 after i.p. administration than after i.v. treatment, whereas in the center of the tumor no concentration difference could be detected. The penetration depth of CDDP lay between 1 and 2 mm and was calculated from the differences in Pt concentration after i.p. and i.v. treatment. This indicates that the effective advantage of i.p. chemotherapy with CDDP in cases of cancers limited to the peritoneal cavity is accentuated at the periphery of the tumor.

Effect of intraperitoneal cetuximab administration on colonic anastomosis and early postoperative adhesion formation in a rat model

“…Clinical studies reported that these patients have prolonged survival rates (15-17). One of the main advantage of IPC is better penetration of chemotherapeutic agents to the tumor nodules where the blood supply is poor (18). Intraperitoneal chemotherapy prevents micrometastases, local recurrence and distant metastases (2,19).…”

Gastric cancer: prevention and treatment of peritoneal metastases

“…Therefore, an adequate lymphadenectomy is essential. Intraperitoneal chemotherapy enters the peritoneal nodule by simple diffusion so it only penetrates to 1 or 2 mm [28] . It is not effective in lymph nodes.…”

Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer

“…This model implies that there is an exponential concentration decrease of the drug from abdominopelvic cavity across the membrane to the plasma compartment. Consequently, the depth of penetration of the intraperitoneal concentration is very limited and is in the order of 1 to 2 mm [38,39] . Ozols et al [40] confirmed adriamycin penetrating only four to six cell layers of a tumor on the diaphragm in a rodent model.…”